Trial Profile
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PInNACLe
- 04 Dec 2018 Interim results assessing tolerability and molecular response presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results (n=12) assessing the immune effects of nilotinib combined with pegylated-interferon-alpha 2b in a subgroup of newly diagnosed chronic phase chronic myeloid leukemia (CML) patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Protocol-specified interim analysis results (n=33) assesing tolerability of the combination and efficacy as measured by molecular responses presented at the 59th Annual Meeting and Exposition of the American Society of Hematology